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ABSTRACT 
CONTEXT AND OBJECTIVE: Studies on postmenopausal women have reported increased risk of breast cancer relating to the type and duration of 
hormone therapy (HT) used. Women with premature ovarian failure (POF) represent a challenge, since they require prolonged HT. Little is known about 
the impact of prolonged HT use on these women’s breasts. This study aimed to evaluate the effects of one type of HT on the breast density of women 
with POF, compared with postmenopausal women.
DESIGN AND SETTING: Cross-sectional study at the Department of Obstetrics and Gynecology, Universidade Estadual de Campinas (Unicamp).  
METHODS: 31 women with POF and 31 postmenopausal women, all using HT consisting of conjugated equine estrogen combined with 
medroxyprogesterone acetate, and matched according to HT duration, were studied. Mammography was performed on all subjects and was analyzed 
by means of digitization or Wolfe’s classification, stratified into two categories: non-dense (N1 and P1 patterns) and dense (P2 and Dy).
RESULTS: No significant difference in breast density was found between the two groups through digitization or Wolfe’s classification. From digitization, 
the mean breast density was 24.1% ± 14.6 and 18.1% ± 17.2 in the POF and postmenopausal groups, respectively (P = 0.15). Wolfe’s classification 
identified dense breasts in 51.6% and 29.0%, respectively (P = 0.171).
CONCLUSION: There was no difference in breast density between the women with POF and postmenopausal women, who had used HT for the same 
length of time. These results may help towards compliance with HT use among women with POF.
RESUMO 
CONTEXTO E OBJETIVO: Estudos com mulheres na pós-menopausa relatam aumento no risco de câncer de mama relacionado ao tipo e duração da 
terapia hormonal (TH) utilizada. Mulheres com falência ovariana prematura (FOP) representam desafio por necessitarem de TH prolongada. Pouco se 
conhece sobre ação da TH nas mamas dessas mulheres. Este estudo objetivou avaliar os efeitos de um tipo de TH sobre a densidade mamária de 
mulheres com FOP comparativamente à de mulheres pós-menopausa.
TIPO DE ESTUDO E LOCAL: Estudo de corte transversal no Departamento de Tocoginecologia, Universidade Estadual de Campinas (Unicamp).
MÉTODOS: Estudaram-se 31 mulheres com FOP e 31 mulheres na pós-menopausa, todas usando TH com estrogênio conjugado equino mais acetato 
de medroxiprogesterona, pareadas pelo tempo de utilização da TH. Todas realizaram mamografia, analisada por digitalização e por classificação de 
Wolfe, estratificada em duas categorias: não densa (padrão N1 e P1) e densa (P2 e Dy).
RESULTADOS: Não houve diferença significativa entre a densidade mamária dos  grupos analisadas por digitalização ou classificação de Wolfe. Pela 
digitalização, calculou-se densidade mamária média em 24.1% ± 14.6 e 18.1% ± 17.2 nas com FOP e pós-menopausa, respectivamente (P = 
0,15); pela classificação de Wolfe identificou-se mamas densas em 51,6% e 29,0%, respectivamente (P = 0,171).
CONCLUSÃO: Não se observou diferença na densidade mamária de mulheres com FOP comparativamente à de mulheres na pós-menopausa 
utilizando TH pelo mesmo período de tempo. Estes resultados podem auxiliar na aderência à TH de pacientes com FOP.
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INTRODUCTION
Studies carried out on postmenopausal women have shown in-
creased risk of breast cancer relating to the type of hormone therapy 
(HT) used and the duration of its use.1-7 It is still a matter for debate 
whether HT causes a reduction in the sensitivity and specificity of mam-
mographic screening as a result of the increase in breast density.8-10 The 
absolute risk of developing breast cancer, for a postmenopausal woman 
using estrogen-progestin HT, is individually very low (an increase of 
eight cases per 10,000 women annually). However, the cumulative ef-
fect has greater repercussions and is not considered insignificant in the 
case of prolonged use.11
Sao Paulo Med J. 2010; 128(4):211-4
Soares PM, Cabello C, Magna LA, Tinois E, Benetti-Pinto CL
212
Women with premature ovarian failure (POF) represent a challenge, 
since they require prolonged hormone therapy in view of their early loss 
of gonad function. However, little is known about the impact of pro-
longed HT use on these women’s breasts.11 Concern about breast cancer 
is one of the most frequent causes of discontinuation of HT.12
Recently, postmenopausal changes in breast density, as evaluated by 
mammography, have been considered to be a strong marker for the risk 
of breast cancer. Breast density has been shown to reveal information 
on the exposure to endogenous and exogenous hormones that affect the 
environment in which cancer originates and develops.10 Various stud-
ies have shown that women with denser breasts have a two to six-fold 
higher risk of developing cancer, compared with women with less dense 
breasts.13-17 
Much information linking HT and breast density in postmeno-
pausal women has been published in the literature.7,18-23 However, to the 
best of our knowledge, no papers evaluating the breast density of wom-
en with POF have been published, even though these women are fre-
quently treated with HT in the same way as postmenopausal women.
OBJECTIVE
Considering the scientific evidence, the questions regarding the ef-
fect of estrogen-progestin hormone therapy on postmenopausal breast 
density and the lack of information on women with premature ovarian 
failure regarding this subject, a study was carried out to compare breast 
densities between women with POF who were using estrogen-progestin 
HT and postmenopausal women using the same type of HT for simi-
lar lengths of time.
MATERIAL AND METHODS
This cross-sectional pilot study evaluated 31 women between 30 
and 40 years of age with a diagnosis of POF shown by secondary amen-
orrhea with hypergonadotropic hypoestrogenism, with follicle-stimu-
lating hormone (FSH) > 40 mIU/ml at two different times.24 These 
women were receiving care at the gynecological endocrinology outpa-
tient clinic of the Department of Obstetrics and Gynecology, Univer-
sidade Estadual de Campinas (Unicamp), and they had been using an 
estrogen-progestin HT regimen composed of 0.625 mg of conjugat-
ed equine estrogen (CEE) combined with medroxyprogesterone ace-
tate (MPA), cyclically or continuously, for at least 12 months. Women 
who had some form of pathological condition and/or had undergone 
previous breast surgery, women who smoked more than 20 cigarettes/
day and those with body mass index (BMI) > 30 kg/m2 were excluded 
from the study.
This group was compared with a control group of 31 postmeno-
pausal women who were using the same hormone therapy as a cyclic or 
continuous regimen. The control group women were matched with the 
women in the study group according to duration of hormone use (± 11 
months). They were selected from the menopause clinic of the Depart-
ment of Obstetrics and Gynecology, Unicamp. Women over 50 years of 
age for whom the menopause had been diagnosed at least 12 months 
previously were eligible for inclusion in the study. The exclusion criteria 
were identical to those of the study group. 
All the women in both groups underwent mammography, and the 
data were analyzed and compared using both the technique of mammo-
graphic digitization25 and Wolfe’s classification.26 However, the patients 
were stratified into only two groups: non-dense breasts (N1 and P1 pat-
terns) and dense breasts (P2 and Dy patterns).
The study protocol was approved by the Institutional Review Board 
of the Department of Obstetrics and Gynecology, Unicamp, and by the 
Ethics Committee of the School of Medicine, Unicamp.
Mammography was carried out using a high-resolution scanner 
(CGR Senographe 500T, GE Medical Systems) with a Kodak RPX-
OMAT processor. Kodak diagnostic films were used, and the left mid-
lateral oblique incidence was used for digitization.
The mammogram films were placed on a negatoscope-type appara-
tus and covered by a sheet of transparent tracing paper. The outlines of 
the images corresponding to the fibroglandular and fatty portions were 
sketched by a specialist in mammography. Areas with the same density as 
the pectoralis major muscle were considered to be fibroglandular, while 
the remainder was considered to be fatty tissue. The drawings were digi-
tized using a Hewlett Packard scanner and an IBM 486 desktop computer 
(DX4, 8 RAM, 540 HD). Digitization fragmented the figure into small 
areas referred to as pixels (picture elements). In the computer, the images 
were opened using an image editing software program (Paintbrush, Mi-
crosoft), in which the fatty areas were colored light grey and the fibroglan-
dular areas were colored black. A numerical value of 250 was attributed to 
the light grey areas and zero to the black areas. The images were evaluated 
using the Mathlab4 software program by a specialist in physics, to quan-
tify the percentage of glandular tissue in relation to the total volume of the 
breast, thus resulting in the dependent variable of breast density.
Evaluation of breast density was also carried out in accordance with 
Wolfe’s classification. However, it was subdivided into only two catego-
ries: non-dense (N1 and P1 patterns, i.e. fibroglandular tissue accounting 
for < 25% of the breast volume in the left mid-lateral oblique incidence) 
and dense (P2 and Dy patterns, i.e. fibroglandular tissue accounting for ≥ 
25% of the breast in the left mid-lateral oblique incidence). The special-
ist in mammography and the physicist who performed the analyses were 
blinded with regard to the identities of the groups.
Means and standard deviations were calculated to analyze the vari-
ables of age, parity and BMI. For the comparison of breast density be-
tween groups (digitization technique), Student’s t-test for independent 
groups was used after performing the Kolmogorov-Smirnov test for nor-
mality. For analysis on Wolfe’s classification, stratified into two catego-
ries, proportions were compared using the chi-square test in contingen-
cy tables.27 The significance level was established at 5%. The software 
used for the statistical analyses was the Statistical Package for the Social 
Sciences (SPSS), version 15.0 for Windows 2006.
RESULTS
The mean age of the women with POF was 36.9 ± 2.9 years and the 
mean age of the postmenopausal women was 58.4 ± 5.1 years (variable 
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Table 1. Breast density of women with premature ovarian failure (POF) and 
postmenopausal women (n = 31 in each group) analyzed according to 
digitization and Wolfe’s classification
Breast density according to mammographic digitization
POF Postmenopausal (controls)
% Breast density
Mean SD Mean SD P-value
24.1 14.6 18.1 17.2 0.15*
Breast density according to Wolfe’s classification
% non-dense 48.4 71.0 0.171†
% dense 51.6 29.0 0.171†
P-value < 0.05; *Student’s t test; †Chi-square test (χ2). SD = standard deviation.
approximately normally distributed in both groups: P = 0.388 and P = 
0.652 respectively). The two groups were paired according to the dura-
tion of hormone therapy use (± 11 months). Hormone therapy (CEE + 
MPA) had been used for a mean of 50.3 ± 39.0 months by women in 
the POF group and for a mean of 50.1 ± 38.4 months by the women 
in the postmenopausal control group (variable also approximately nor-
mally distributed in both groups: P = 0.386 and P = 0.403 respectively). 
There was no statistically significant difference in duration of HT use 
between the two groups (P = 0.98). The mean time since diagnosis of 
POF was 85.9 ± 44.4 months, whereas the mean time since diagnosis of 
menopause was 117.7 ± 57.6 months (this variable also being approxi-
mately normally distributed in both groups: P = 0.870 and P = 0.680 
respectively).
With regard to the other variables evaluated, the women with POF 
had had fewer pregnancies than had the postmenopausal women (1.5 ± 
1.7 and 3.7 ± 2.6 pregnancies, respectively, P < 0.001; variable approxi-
mately normally distributed in both groups: P = 0.290 and P = 0.192 
respectively). Fewer of the women with POF had breastfed than had 
the women in the control group (54.8% of the women with POF and 
81.7% of the control group, P = 0.005).
Although women with BMI > 30 kg/m2 had been excluded from 
enrollment in the study, the difference in BMI between the group with 
POF (24.1 ± 3.2) and the control group (25.8 ± 3.3) was statistically 
significant (P = 0.04). BMI was approximately normally distributed in 
both groups (P = 0.809 and P = 0.480 respectively).
The percentage of breast density analyzed using mammographic 
digitization, a variable that was approximately normally distributed in 
both groups (P = 0.976 and P = 0.268 respectively), was 24.1 ± 14.6% 
in the POF group and 18.1 ± 17.2% in the control group. This differ-
ence was not statistically significant (P = 0.15). Wolfe’s classification, 
stratified into two subgroups (non-dense: fibroglandular tissue occupy-
ing an area < 25% of the breast; and dense: fibroglandular tissue occupy-
ing an area ≥ 25% of the breast), also failed to detect any statistically sig-
nificant difference in breast density between the two groups, although 
51.6% of the women with POF had dense breasts, compared with only 
29% of the postmenopausal group (P = 0.171) (Table 1).
DISCUSSION
No difference in breast density was found between the women 
with POF and the postmenopausal women using hormone therapy 
with conjugated equine estrogens and medroxyprogesterone acetate 
for similar periods of time, either when analyzed objectively using 
digitization or subjectively in accordance with Wolfe’s classification. 
However, in both groups, the percentage of fibroglandular tissue in re-
lation to the total area of the breast was low (24.1 ± 14.6% and 18.1 
± 17.2%, respectively).
In the POF group, which was composed of younger women (mean 
age 36.9 ± 2.9 years), the mean time elapsed since gonad failure was 
shorter than in the control group. Other factors that could have protec-
tively contributed towards the reduction in breast density were in fact 
less frequent in the POF group, in which the women had had fewer 
pregnancies and fewer women had breastfed. Despite these characteris-
tics, breast density in the study group was no different from that of the 
control group.
This study does not enable conclusions to be reached regarding the 
causes of this finding, but one hypothesis may be that the hypoestro-
genism following gonad failure, which would cause regression of fi-
broglandular tissue and its progressive replacement by fatty tissue,18,20 
may have greater repercussions in reducing breast density when present 
at a younger age.
One concern regarding increased breast density resulting from estro-
gen-progestin replacement therapy relates to impaired mammographic 
sensitivity and specificity. This would result in a higher number of false-
positive results, since the dense glandular tissue tends to make identifi-
cation of tumorous masses more difficult,9,10 thereby compromising the 
early diagnosis of breast cancer.8
Hormone therapy is known to increase the density of the 
breast parenchyma. However, this does not occur in the majority of 
women,18,20,22,28 and this stimulus is also known to vary according to 
the type of hormone therapy used. In view of these factors, the groups 
were matched for duration of HT use and for the type of hormone used 
(CEE + MPA), Nonetheless, matching for exclusively cyclic or continu-
ous use was not possible, since younger women with POF often want to 
menstruate, whereas postmenopausal women prefer continuous regimes 
in order to avoid bleeding.
Although age has been shown to have an inverse correlation with 
breast density,29 this association was not found in the study group or in 
the control group of postmenopausal women. Although the women in 
the study group were younger, their breast density was similar to that of 
the older postmenopausal women. 
No significant difference in breast density was found between the 
two groups in this study, despite the fact that the groups had very dif-
ferent characteristics. This latter point has encouraged us to proceed 
with designing a new, prospective study involving data correlation that 
would enable greater precision of control over the variables that affect 
each woman participating in the study.
Finally, based on the results from this pilot study, and considering 
the likelihood of type I error as 0.05 (alpha = 0.05) and a test power 
(type II error) of 80% (1 - beta = 0.80), we recommend that for fur-
ther studies, a sample size of at least 92 patients in each group should 
be used.
It is important to take into account the fact that the diagnosis of 
POF is  established at a rate of about one case for every 1,000 women. 
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This ratio may make it hard to achieve bigger samples than the pres-
ent one. 
Although the authors are aware of the limitations of the present 
sample size, this was a pilot study. Hence, the findings described here 
are important because this is the first paper reporting on the effects of 
estrogen-progestin HT on the breast density of women with POF com-
pared to that of postmenopausal women using the same type of HT for 
similar periods of time. 
The patients enrolled in this study are being followed up for pro-
spective evaluation proposals. 
Finally, it should be stressed that the question of hormone treat-
ment remains open. New studies would be necessary, with bigger sam-
ple sizes if possible, in order to answer women’s concerns and thus pro-
mote better compliance with treatment. 
CONCLUSIONS
There was no difference in breast density between the women with 
POF and the postmenopausal women who had used the same HT dur-
ing similar periods. 
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